A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III Non-small-cell lung cancer (NSCLC)

International Journal of Radiation Oncology Biology Physics

Volumn 61, Issue 4, 2005, Pages 1117-1122

  Ishikura, Satoshi ^a   Ohe, Yuichiro ^a   Nihei, Keiji ^a   Kubota, Kaoru ^a   Kakinuma, Ryutaro ^a   Ohmatsu, Hironobu ^a   Goto, Koichi ^a   Niho, Seiji ^a   Nishiwaki, Yutaka ^a   Ogino, Takashi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemoradiotherapy; Hyperfractionated accelerated radiation therapy; Non small cell lung cancer

Indexed keywords

CELLS; CHEMOTHERAPY; PATIENT TREATMENT; TOXICITY; TUMORS;

HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART); NON-SMALL-CELL LUNG CANCER; PERFORMANCE STATUS (PS); PROGRESSION-FREE SURVIVAL;

RADIOTHERAPY;

CISPLATIN; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE DISEASE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; FIBROSIS; HUMAN; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NAUSEA; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION PNEUMONIA; RIB FRACTURE; SUBCUTANEOUS TISSUE; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; TREATMENT FAILURE; VINBLASTINE;

EID: 20044369003     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.07.692     Document Type: Article

References (29)

1. The editorial board of the cancer statistics in Japan (ed). Cancer statistics in Japan 2003. Foundation for promotion of cancer research. http://www.ncc.go.jp/en/statistics/2003/data03.pdf.
2. R.O. Dillman, J. Herndon, S.L. Seagren Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
3. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials Br Med J 311 1995 899 909
4. C. Schaake-Koning, W. van den Bogaert, O. Dalesio Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 326 1992 524 530
5. W.T. Sause, C. Scott, S. Taylor 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer Radiation Therapy Oncology Group (RTOG) J Natl Cancer Inst 87 1995 198 205
6. W. Sause, P. Kolesar, S. Taylor Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 117 2000 358 364
7. K. Furuse, M. Fukuoka, M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
8. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 94-10 [Abstract]. Proc Am Soc Clin Oncol 2003;22:621a.
9. M. Saunders, S. Dische, A. Barrett Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial Radiother Oncol 52 1999 137 148
10. M.P. Mehta, S.P. Tannehill, S. Adak Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593 J Clin Oncol 16 1998 3518 3523
11. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
12. R.W. Byhardt, C.B. Scott, D.S. Ettinger Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer Results of Radiation Therapy Oncology Group 90-15 Cancer 75 1995 2337 2344
13. Zemanova M, Petruzelka L, Zemanova M. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study [Abstract]. Proc Am Soc Clin Oncol 2002;21:290a.
14. F. Macbeth An uncharted country Clin Oncol (R Coll Radiol) 11 1999 71 72
15. M.I. Saunders Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care Lancet Oncol 2 2001 401 408
16. M.I. Saunders, A. Rojas, B.E. Lyn Dose-escalation with CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer Clin Oncol 14 2002 352 360
17. S.M. Bentzen, M.I. Saunders, S. Dische From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome Clin Oncol 14 2002 372 381
18. M. Baumann, T. Herrmann, W. Matthiessen CHARTWEL-Bronchus (ARO 97-1): A randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-cell bronchial carcinoma Strahlenther Onkol 173 1997 663 667
19. Belani CP, Wang W, Johnson DH, et al. Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA & B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) [Abstract]. Proc Am Soc Clin Oncol 2003;22:622a.
20. K. Kelly, J. Crowley, P.A. Bunn Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial J Clin Oncol 19 2001 3210 3218
21. DG Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 J Clin Oncol 22 2004 330 353
22. Graham MV, Winter K, Purdy JA, et al. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311), a dose escalation study using 3D conformal radiation therapy in patients with inoperable nonsmall cell lung cancer [Abstract]. Int J Radiat Oncol Biol Phys 2001;51:20S.
23. K.E. Rosenzweig, S.E. Sim, B. Mychalczak Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 50 2001 681 685
24. J.A. Hayman, M.K. Martel, R.K. Ten Haken Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial J Clin Oncol 19 2001 127 136
25. Thirion P, Mc Gibney C, Holmberg O, et al. 3-dimensional conformal radiation therapy (3DCRT) permits radiobiological dose escalation for non-small-cell lung cancer (NSCLC): Preliminary results of a phase I/II trial [Abstract]. Proc Am Soc Clin Oncol 2001;20:344a.
26. D.R. Gandara, K. Chansky, K.S. Albain Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
27. L. Milas, Z. Fan, N.H. Andratschke Epidermal growth factor receptor and tumor response to radiation: In vivo preclinical studies Int J Radiat Oncol Biol Phys 58 2004 966 971
28. J.S. Ochs Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors Int J Radiat Oncol Biol Phys 58 2004 941 949
29. H. Choy, L. Milas Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst 95 2003 1440 1452